Early Stage p53 Program Lands Ascenta $398M Deal with Sanofi

In its first major collaboration since being founded in 2003, privately held Ascenta Therapeutics Inc. partnered an early stage cancer program with Sanofi-Aventis SA in exchange for up to $398 million in up-front and milestone payments, plus tiered royalties on any products that make it to market. (BioWorld Today)